Atherosclerosis

Atherosclerosis – Study Guide for Medical Students

Definition

Atherosclerosis is a chronic, progressive disease of medium and large arteries characterized by endothelial dysfunction, lipid accumulation, inflammation, and fibrous plaque formation within the intima, leading to luminal narrowing, impaired blood flow, and potential plaque rupture with thrombosis.

It is the underlying pathology in most cases of coronary artery disease (CAD), cerebrovascular disease, and peripheral arterial disease (PAD), and is a central cause of morbidity and mortality worldwide.

Epidemiology

Atherosclerosis is highly prevalent and increases with age, accounting for the majority of cardiovascular disease (CVD) events globally.

• Age: Incidence and severity increase with advancing age; significant plaque burden typically appears from middle age onward.
• Sex: More common and earlier onset in males; women catch up after menopause due to loss of estrogen’s protective effect.
• Geography and lifestyle: Higher prevalence in high-income countries and urbanized populations with diets high in saturated fat, smoking, and low physical activity; incidence is rising in low- and middle-income countries.
• Global burden: Atherosclerotic cardiovascular disease remains the leading cause of death worldwide, driving ischemic heart disease and ischemic stroke.

Pathophysiology

Atherosclerosis is best understood as a chronic inflammatory and lipid-driven process involving the arterial intima.

1. Endothelial dysfunction and injury

• Initiating factors include hypertension, dyslipidemia (especially elevated LDL), smoking, diabetes, obesity, and systemic inflammation.
• These factors cause endothelial dysfunction with decreased nitric oxide (NO) production, increased permeability, and expression of adhesion molecules (VCAM-1, ICAM-1).
• Endothelial dysfunction allows LDL and other lipoproteins to enter and accumulate in the intima.

2. Lipoprotein entry and modification

• LDL and very low-density lipoprotein (VLDL) remnants migrate into the intima at sites of disturbed flow (branch points, curvatures).
• Within the intima, LDL becomes oxidized and otherwise modified, making it pro-inflammatory and chemotactic.
• Oxidized LDL stimulates endothelial cells to express chemokines (e.g., MCP-1) and pro-inflammatory cytokines.

3. Monocyte recruitment and foam cell formation

• Circulating monocytes adhere to activated endothelium, migrate into the intima, and differentiate into macrophages.
• Macrophages uptake oxidized LDL via scavenger receptors (e.g., SR-A, CD36), becoming foam cells.
• Accumulation of foam cells forms fatty streaks, the earliest visible lesion of atherosclerosis.

4. Smooth muscle cell (SMC) migration and plaque formation

• Growth factors (PDGF, FGF) and cytokines stimulate medial SMCs to migrate into the intima and proliferate.
• SMCs synthesize extracellular matrix (collagen, elastin, proteoglycans), forming a fibrous component.
• This leads to development of a fibrofatty plaque with a necrotic lipid core (foam cells, extracellular lipids, cell debris) covered by a fibrous cap of SMCs and collagen.

5. Plaque progression and remodeling

• Ongoing lipid accumulation, cell death, and inflammation expand the necrotic core.
• Plaques may remain stable with a thick fibrous cap and smaller lipid core or become vulnerable with a thin cap, large lipid core, and intense inflammation.
• Arterial remodeling can initially preserve lumen size (positive remodeling) but eventually leads to luminal narrowing (negative remodeling).

6. Plaque rupture, erosion, and thrombosis

• Plaque rupture occurs when the fibrous cap breaks, exposing thrombogenic core contents (tissue factor, collagen) to circulating blood.
• Platelet adhesion, activation, and aggregation lead to thrombus formation; fibrin stabilizes the clot.
• Thrombus may cause acute vessel occlusion (e.g., STEMI, acute ischemic stroke) or partial obstruction (unstable angina, TIA).
• Plaque erosion without rupture can also trigger thrombosis, especially in younger patients and women.

7. Clinical correlation by vascular bed

• Coronary arteries: Stable angina, acute coronary syndrome (unstable angina, NSTEMI, STEMI), sudden cardiac death.
• Cerebral arteries/carotids: Ischemic stroke, TIA, vascular dementia.
• Peripheral arteries: Intermittent claudication, critical limb ischemia, limb loss.
• Renal arteries: Renovascular hypertension, ischemic nephropathy.
• Aorta: Aneurysm formation, atheroembolic disease.

Risk Factors

Atherosclerosis is driven by a combination of non-modifiable and modifiable risk factors. Many are shared across cardiovascular diseases.

Non-modifiable risk factors

• Age: Risk increases with age.
• Sex: Men are at higher risk until women reach menopause.
• Family history: Premature ASCVD (e.g., <55 years in male first-degree relative, <65 years in female) increases risk.
• Genetic disorders: Familial hypercholesterolemia, familial combined hyperlipidemia, and other dyslipidemias.

Modifiable risk factors

• Dyslipidemia: Elevated LDL-C, elevated non-HDL-C, elevated ApoB, low HDL-C, high triglycerides (especially as part of metabolic syndrome).
• Hypertension: Chronic elevated blood pressure accelerates endothelial damage.
• Diabetes mellitus and insulin resistance: Strongly associated with atherogenic dyslipidemia and endothelial dysfunction.
• Smoking: Promotes oxidative stress, endothelial injury, and prothrombotic state.
• Obesity and metabolic syndrome: Central obesity, hypertension, hyperglycemia, and dyslipidemia cluster to increase risk.
• Physical inactivity: Associated with impaired lipid profile and insulin resistance.
• Unhealthy diet: High in saturated and trans fats, refined carbohydrates, and low in fruits, vegetables, and whole grains.
• Chronic kidney disease: Associated with accelerated atherosclerosis and vascular calcification.
• Chronic inflammatory conditions: e.g., rheumatoid arthritis, psoriasis, SLE.

Clinical Presentation

Atherosclerosis is often clinically silent for decades. Symptoms depend on the vascular bed involved and whether disease is stable or acute.

Coronary artery disease (CAD)

• Stable angina pectoris: Exertional chest discomfort (pressure, tightness) relieved by rest or nitroglycerin; due to fixed coronary stenosis.
• Acute coronary syndrome (ACS): Unstable angina, NSTEMI, STEMI caused by plaque rupture or erosion with thrombosis.
• Ischemic cardiomyopathy: Chronic ischemia leading to LV dysfunction and heart failure.

Cerebrovascular disease

• Transient ischemic attack (TIA): Focal neurological deficits lasting <24 hours (usually <1 hour).
• Ischemic stroke: Persistent focal deficits due to infarction from carotid or intracranial atherosclerosis or artery-to-artery embolism.
• Vascular cognitive impairment: Chronic small vessel and large vessel disease causing cognitive decline.

Peripheral arterial disease (PAD)

• Intermittent claudication: Exertional muscle pain (typically calf) relieved by rest.
• Critical limb ischemia: Rest pain, non-healing ulcers, gangrene.
• Signs: Diminished pulses, cool extremities, trophic skin changes, bruits.

Renal artery stenosis

• Resistant or accelerated hypertension.
• Unexplained decline in renal function, particularly after ACEi/ARB initiation in bilateral disease.
• Abdominal or flank bruit may be present.

Aortic and other large vessel involvement

• Abdominal aortic aneurysm (AAA): Often asymptomatic; may present as pulsatile abdominal mass, back or abdominal pain, or rupture.
• Atheroembolism: Cholesterol emboli causing livedo reticularis, blue toe syndrome, renal dysfunction.

Diagnosis

Diagnosis of atherosclerotic disease involves assessment of risk factors, identification of clinical manifestations by vascular territory, and use of appropriate imaging and laboratory tests.

Clinical assessment

• Detailed history of chest pain, claudication, neurological symptoms, rest pain, and functional capacity.
• Assessment of risk factors: hypertension, diabetes, lipid profile, smoking, family history.
• Physical examination: BP in both arms, cardiac exam, carotid and peripheral pulses, bruits, signs of heart failure or PAD.

Laboratory tests

• Lipid profile: Total cholesterol, LDL-C, HDL-C, triglycerides; sometimes ApoB and lipoprotein(a).
• Glucose metabolism: Fasting glucose, HbA1c; oral glucose tolerance test if indicated.
• Renal function: Serum creatinine, eGFR, urine albumin.
• Inflammatory markers: hs-CRP may be used for risk stratification in some settings.

Imaging and functional tests by vascular bed

Coronary arteries

• Exercise stress testing: Treadmill ECG test for suspected stable angina in appropriate candidates.
• Stress imaging: Stress echocardiography, nuclear perfusion imaging, or stress cardiac MRI for higher diagnostic accuracy.
• Coronary CT angiography (CCTA): Non-invasive anatomic imaging of coronary arteries; useful in intermediate risk patients.
• Coronary artery calcium (CAC) scoring: Quantifies calcified plaque; used in primary prevention for risk stratification.
• Invasive coronary angiography: Gold standard for luminal assessment; used in high-risk or symptomatic patients, especially when revascularization is being considered.

Cerebrovascular and carotid disease

• Carotid duplex ultrasound: First-line for carotid stenosis.
• CT angiography (CTA) or MR angiography (MRA): For detailed vascular imaging of carotid and intracranial arteries.
• Brain MRI/CT: To assess for ischemic infarcts and hemorrhage.

Peripheral arterial disease (PAD)

• Ankle-brachial index (ABI): Ratio of ankle to brachial systolic pressure; ≤0.90 suggests PAD, <0.40 indicates severe disease.
• Doppler ultrasound: Segmental pressures and waveform analysis to localize lesions.
• CTA/MRA: For anatomic delineation prior to intervention.
• Conventional angiography: Gold standard and used when planning endovascular therapy.

Renal artery and aortic disease

• Duplex ultrasonography: Screening for AAA and evaluating renal artery stenosis.
• CTA/MRA: Detailed imaging of aorta and renal arteries; important for planning interventions.

Management

Management of atherosclerosis includes lifestyle modification, risk factor control, pharmacotherapy to stabilize plaques and reduce events, and revascularization when indicated.

Lifestyle and risk factor modification

• Smoking cessation: Strongly recommended; reduces cardiovascular risk substantially.
• Dietary modification: Emphasis on Mediterranean-style or similar diets rich in fruits, vegetables, whole grains, legumes, nuts, fish, and unsaturated fats; limit saturated and trans fats, refined carbohydrates, and excessive sodium.
• Physical activity: At least 150 minutes/week of moderate-intensity aerobic activity or 75 minutes/week vigorous activity, plus muscle-strengthening activities.
• Weight management: Aim for BMI in the healthy range and reduction in central obesity (waist circumference).
• Alcohol: If consumed, limit to modest amounts; heavy use increases risk.

Pharmacologic therapy

Lipid-lowering therapy

• Statins (HMG-CoA reductase inhibitors): First-line for primary and secondary prevention; reduce LDL-C and have pleiotropic effects stabilizing plaques and reducing inflammation.
• Intensity selection: High-intensity statins (e.g., atorvastatin 40–80 mg, rosuvastatin 20–40 mg) for established ASCVD or very high risk; moderate-intensity for intermediate risk or statin-intolerant patients.
• Ezetimibe: Add-on to statin if LDL-C goals not met or in statin intolerance.
• PCSK9 inhibitors: For very high-risk patients with persistently elevated LDL-C despite maximally tolerated statin ± ezetimibe, or familial hypercholesterolemia.
• Other agents: Bempedoic acid, bile acid sequestrants, or triglyceride-lowering agents (e.g., icosapent ethyl) in selected cases.

Antiplatelet therapy

• Secondary prevention: Aspirin (75–100 mg daily) is standard for patients with established ASCVD, unless contraindicated.
• Dual antiplatelet therapy (DAPT): Aspirin plus a P2Y12 inhibitor (e.g., clopidogrel, ticagrelor, prasugrel) after ACS or percutaneous coronary intervention (PCI) for a defined period.
• Primary prevention: Aspirin is not routinely recommended; reserved for selected high-risk individuals where benefits outweigh bleeding risk.

Blood pressure control

• Target blood pressure generally <130/80 mmHg in most patients with ASCVD or high risk, individualized based on comorbidities and tolerance.
• First-line agents: ACE inhibitors or ARBs, thiazide or thiazide-like diuretics, calcium channel blockers; beta-blockers particularly indicated post-MI or in angina/heart failure.

Glycemic control in diabetes

• Target HbA1c individualized, often around <7%, balancing microvascular benefits with hypoglycemia risk and comorbidities.
• SGLT2 inhibitors and GLP-1 receptor agonists have proven cardiovascular benefits in high-risk patients with type 2 diabetes.

Other pharmacologic strategies

• ACE inhibitors/ARBs: Recommended in many patients with CAD, diabetes, CKD, or heart failure for vascular protection.
• Beta-blockers: Key post-MI and in angina or LV dysfunction.
• Anticoagulation: Indicated for atrial fibrillation, LV thrombus, or other specific conditions, not for atherosclerosis alone.

Revascularization

Revascularization is considered when symptoms remain despite optimal medical therapy or when there is high-risk anatomy or critical ischemia.

Coronary revascularization

• Percutaneous coronary intervention (PCI): Balloon angioplasty with stent placement (usually drug-eluting stents) for suitable coronary lesions.
• Coronary artery bypass grafting (CABG): Preferred in multivessel disease with LV dysfunction, left main disease, or complex anatomy.

Peripheral and carotid revascularization

• Peripheral angioplasty and stenting: For lifestyle-limiting claudication or limb-threatening ischemia in PAD.
• Endarterectomy or stenting: Carotid endarterectomy or carotid artery stenting in selected patients with significant carotid stenosis and appropriate symptoms/risk profile.
• Bypass surgery: For extensive PAD or when endovascular options are limited.

Renal artery and aortic interventions

• Renal artery stenting: Reserved for selected patients with hemodynamically significant stenosis and specific indications.
• Endovascular aneurysm repair (EVAR) or open surgical repair: For abdominal aortic aneurysms meeting size or growth criteria.

Key Clinical Pearls

• Atherosclerosis is a systemic disease; involvement in one vascular bed often implies disease in others. Always consider global vascular risk.
• Plaque burden and vulnerability, not just degree of stenosis, determine risk of acute events; non-obstructive plaques can still rupture.
• LDL-C reduction with statins is one of the most powerful interventions for reducing ASCVD risk; high-intensity statins are standard in secondary prevention.
• Smoking cessation and lifestyle modifications have major relative risk reductions and should be emphasized alongside pharmacotherapy.
• Diabetes and CKD markedly accelerate atherosclerosis; these patients are often treated as very high cardiovascular risk.
• An ABI ≤0.90 is a simple, inexpensive tool to diagnose PAD and indicates increased cardiovascular risk even if asymptomatic.
• Stable angina reflects fixed stenosis, while sudden worsening or rest symptoms suggest plaque instability and possible ACS.
• In carotid disease, intervention decisions are based on both degree of stenosis and the presence of symptoms (e.g., TIA or stroke).
• Vascular prevention is multidimensional: lipid control, BP management, glycemic control, antiplatelets (when indicated), and lifestyle change all contribute.
• Early recognition and treatment of risk factors in young adulthood can significantly reduce lifetime risk of atherosclerotic events.